PharmaCorp Rx Inc.
PharmaCorp Rx Inc. operates retail pharmacies under the PharmaChoice name in Canada. It offers prescription drug and custom compounding specialization services; weight loss and lifestyle management solutions, including health and wellness products; and convenience and confectionary products. The company was incorporated in 2021 and is headquartered in Saskatoon, Canada.
PharmaCorp Rx Inc. (PCRX) - Total Liabilities
Latest total liabilities as of September 2025: CA$9.50 Million CAD
Based on the latest financial reports, PharmaCorp Rx Inc. (PCRX) has total liabilities worth CA$9.50 Million CAD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PharmaCorp Rx Inc. - Total Liabilities Trend (2021–2024)
This chart illustrates how PharmaCorp Rx Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PharmaCorp Rx Inc. Competitors by Total Liabilities
The table below lists competitors of PharmaCorp Rx Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sakar Healthcare Limited
NSE:SAKAR
|
India | ₹1.45 Billion |
|
JCH Systems Inc
KQ:033320
|
Korea | ₩42.00 Billion |
|
PT Eagle High Plantations Tbk
F:7B7
|
Germany | €7.01 Trillion |
|
RATH Aktiengesellschaft
VI:RAT
|
Austria | €70.66 Million |
|
Cyberfuels Holding Company Inc.
PINK:CBRF
|
USA | $31.22 Million |
|
Tplex Co. Ltd
KQ:081150
|
Korea | ₩77.04 Billion |
|
Ilji Technology Co. Ltd
KQ:019540
|
Korea | ₩460.54 Billion |
|
Sinil Pharmaceutical Co. Ltd
KQ:012790
|
Korea | ₩18.23 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down PharmaCorp Rx Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmaCorp Rx Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmaCorp Rx Inc. (2021–2024)
The table below shows the annual total liabilities of PharmaCorp Rx Inc. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$4.64 Million | +9952.57% |
| 2023-12-31 | CA$46.19K | +180.50% |
| 2022-12-31 | CA$16.46K | -37.50% |
| 2021-12-31 | CA$26.34K | -- |